Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors.

Uyoga S, Adetifa IMO, Karanja HK, Nyagwange J, Tuju J, Wanjiku P, Aman R, Mwangangi M, Amoth P, Kasera K, Ng'ang'a W, Rombo C, Yegon C, Kithi K, Odhiambo E, Rotich T, Orgut I, Kihara S, Otiende M, Bottomley C, Mupe ZN, Kagucia EW, Gallagher KE, Etyang A, Voller S, Gitonga JN, Mugo D, Agoti CN, Otieno E, Ndwiga L, Ndwiga L, Lambe T, Wright D, Barasa E, Tsofa B, Bejon P, Ochola-Oyier LI, Agweyu A, Scott JAG, Warimwe GM. · 2021

Read Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors. by Uyoga S, Adetifa IMO, Karanja HK, Nyagwange J, Tuju J, Wanjiku P, Aman R, Mwangangi M, Amoth P, Kasera K, Ng'ang'a W, Rombo C, Yegon C, Kithi K, Odhiambo E, Rotich T, Orgut I, Kihara S, Otiende M, Bottomley C, Mupe ZN, Kagucia EW, Gallagher KE, Etyang A, Voller S, Gitonga JN, Mugo D, Agoti CN, Otieno E, Ndwiga L, Ndwiga L, Lambe T, Wright D, Barasa E, Tsofa B, Bejon P, Ochola-Oyier LI, Agweyu A, Scott JAG, Warimwe GM. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7877494.txt.

Introduction

Uyoga and co-authors report a serology study of COVID-19 spread in Kenya. Blood donors gave samples that the team tested for antibodies against SARS-CoV-2. Antibodies show who has already met the virus, even without a recorded test.

By the end of July 2020, Kenya had reported only 341 deaths. The authors found an overall antibody rate of 4.3% among blood donors. Rates peaked in donors aged 35 to 44 years. The low death toll contrasts with many richer countries. The team links part of that gap to Kenya's young population, with less than 4% aged 65 or older. The findings give an early, ground-level picture of how far the virus had spread in the country.

Catalog record

CREATORUyoga S, Adetifa IMO, Karanja HK, Nyagwange J, Tuju J, Wanjiku P, Aman R, Mwangangi M, Amoth P, Kasera K, Ng'ang'a W, Rombo C, Yegon C, Kithi K, Odhiambo E, Rotich T, Orgut I, Kihara S, Otiende M, Bottomley C, Mupe ZN, Kagucia EW, Gallagher KE, Etyang A, Voller S, Gitonga JN, Mugo D, Agoti CN, Otieno E, Ndwiga L, Ndwiga L, Lambe T, Wright D, Barasa E, Tsofa B, Bejon P, Ochola-Oyier LI, Agweyu A, Scott JAG, Warimwe GM.
YEAR2021
COLLECTIONPAPERS
FORMATTXT
FILE SIZE28 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7877494

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Seroprevalence of anti–SARS-CoV-2 IgG antibodies in Kenyan blood donors By Sophie Uyoga, Ifedayo M O Adetifa, Henry K Karanja, James Nyagwange, James Tuju, Perpetual Wanjiku, Rashid Aman, Mercy Mwangangi, Patrick Amoth, Kadondi Kasera, Wangari Ng’ang’a, Charles Rombo Published in: Science (New York, N.y.) DOI: 10.1126/science.abe1916 ABSTRACT Pandemic progress in Kenya By the end of July 2020, Kenya had reported only 341 deaths and ∼20,000 cases of COVID-19. This is in marked contrast to the tens of thousands of deaths reported in many higher-income countries. The true extent of COVID-19 in the community was unknown and likely to be higher than reports indicated. Uyoga et al. found an overall seroprevalence among blood donors of 4.3%, peaking in 35- to 44-year-old individuals (see the Perspective by Maeda and Nkengasong). The low mortality can be partly explained by the steep demographics in Kenya, where less than 4% of the population is 65 or older. These circumstances combine to result in Kenyan hospitals not currently being overwhelmed by patients with respiratory distress. However, the imposition of a strict lockdown in this country has shifted the disease burden to maternal and child deaths as a result of disruption to essential medical services. Science, this issue p. 79; see also p. 27 Africa accounts for 17% of the global population (1) but by late July 2020 accounted for only 5% of the global COVID-19 cases and 3% of global COVID-19 deaths reported (2). This disparity has been attributed to limited capacity for diagnosis, timely implementation of stringent containment measures, a younger population structure, and a predominance of asymptomatic and mild infections (3, 4). The first case of COVID-19 in Kenya was detected on 12 March 2020. Within 1 week, the government instituted containment measures to limit the spread of the virus (5). By 31 July national surveillance recorded 20,636 cases and 341 deaths (6). This increase in cases is notably slower than the epidemic in Wuhan, Europe, or the United States. Recently, it has been suggested that “the virus is spreading… …with an attenuated outcome in Africa” [(7), p. 626], but there are few data available to confirm or refute this assertion. In countries affected early in the pandemic, serological surveillance was used to define cumulative incidence. For example, at the release of lockdown in Wuhan, 9.6% of staff resuming work were found to have antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (8). At the end of the epidemic wave in Spain, seropositivity was 5.0% in a random population sample of 60,897 (9). As the epidemic curve declined in Geneva, seroprevalence rose over 3 weeks from 4.8 to 10.9% (10). Currently, there are few estimates of SARS-CoV-2 seroprevalence in Africa in the literature (11). Movement restrictions, in response to COVID-19, have limited the conduct of fieldwork for population-based serosurveys. Several countries have monitored seroprevalence in blood transfusion donors (12, 13) or expectant mothers attending antenatal clinics (14). Here, we report the results of a pragmatic national serosurvey using residual blood samples from transfusion donors across Kenya and a highly sensitive and specific assay for anti–SARS-CoV-2 spike immunoglobulin G (IgG). We validated a widely used enzyme-linked immunosorbent assay (ELISA) for SARS-CoV-2 IgG (15) with 910 serum samples from the prepandemic period and 174 sera from polymerase chain reaction (PCR)–defined SARS-CoV-2 cases, and a well-characterized five-sera panel from the National Institute of Biological Standards and Control (NIBSC) in the UK. For either receptor-binding domain (RBD) or whole spike, specificity was higher when using a ratio of the sample optical density (OD)/negative control OD than when using the raw sample OD plus 3 standard deviations to define seropositivity (table S1). By using OD ratios, both RBD and spike ELISAs correctly classified 901 of 910 prepandemic samples as seronegative (table S1). However, the spike ELISA detected more seropositives (166 of 179 compared with 145 of 179 for RBD ELISA) among sera from SARS-CoV-2 PCR-positive individuals (fig. S2, A and B). On the basis of these data, we defined anti–SARS-CoV-2 IgG seropositivity as an OD ratio >2 and selected the spike ELISA for this study. The sensitivity and specificity, at this threshold, were 92.7% [95% confidence interval (CI), 87.9 to 96.1%] and 99.0% [95% CI, 98.1 to 99.5%], respectively (figs. S3, A and B, S5, and S6; and table S1). As previously noted (15), the RBD and whole-spike ELISA responses were highly correlated (fig. S3C), with very little interassay variation (fig. S4). A total of 3174 blood transfusion samples were collected from four Kenya National Blood Transfusion Service (KNBTS) regional blood transfusion centers that are supported by several satellites and hospitals between 30 April and 16 June 2020, from individuals aged 15 to 66 years. Approximately half of the samples were drawn in Mombasa; the remainder were evenly distributed between Nairobi, Kisumu, and Eldoret (Fig. 1 and table S2). We excluded 18 duplicate samples, 56 records missing data on age or collection date, and two records from individuals aged ≥65 years. Policy in Kenya is to avoid blood donation from individuals >65 years, and we excluded these other data points as potentially unreliable. These exclusions left 3098 samples for further analysis (Fig. 1). [Figure: Participant flow diagram for SARS-CoV-2 seroprevalence study of blood donors in Kenya.Exclusion criteria for the selection of samples with complete data.] Of the 3098 samples, 174 were positive for anti–SARS-CoV-2 spike IgG, giving a crude seroprevalence of 5.6% (95% CI, 4.8 to 6.5%). Crude seroprevalence varied by age (P = 0.046), ranging between 3.4 to 7.0% among adults 15 to 54 years; all 71 donors aged 55 to 64 years were seronegative (Table 1). Crude seroprevalence did not vary by sex (P = 0.50) but did vary geographically, from 1.9% in the Rift Valley region to 10.0% in the Western region (P = 0.002) (Table 1). [Table: Crude, population-weighted, and test performance–adjusted SARS-CoV-2 anti-spike protein IgG seroprevalence by participant characteristics and regions.Prevalence estimates were calculated by using multilevel regression and poststratification (MLRP) to account for differences in the sample population and the national population and subsequently adjusted for assay sensitivity and specificity.] Compared with the 2019 Kenya Population and Housing Census, our participants were more commonly male (82.0% in our study versus 49.3% in the census), had more persons aged 25 to 34 years (40.1 versus 27.3%), and more residents of coastal counties (49.2 versus 9.1%) (Table 2). We therefore adjusted the prevalence estimate for the demographics of the sample using poststratification, and for the sensitivity and specificity of the test. [Table: General characteristics of the study population compared with the national population of Kenya.N is the number of individuals in each stratum.] The Bayesian population-weighted and test-adjusted seroprevalence for Kenya was 4.3% (95% CI, 2.9 to 5.8%) (Table 1), and the posterior sensitivity and specificity estimates were 92.4% (95% CI, 88.0 to 95.6%) and 98.9 (95% CI, 98.2 to 99.5%), respectively. Seroprevalence was higher (4.2 to 5.2%) in the younger age groups (15 to 44 years) and declined in the older age groups (45 to 64 years) but was similar for both sexes. Seroprevalence was highest for those living in Mombasa, Nairobi, and the Western region, although the number of observations for the Western region was small. The directly standardized seroprevalence estimates are presented

Read the complete text